Corporate Research Fronts> Biological Sciences
December 2010
This list of corporate research fronts from Essential Science IndicatorsSM from Thomson Reuters is from the third bimonthly period of 2010, and covers areas in the biological sciences. Source dates are July 31, 2004-June 30, 2010 (sliding 6-year period).
| Research Front Name | % of corp. affiliations | Leading corp. |
|---|---|---|
| SMALL MOLECULE KINASE INHIBITOR CANCER TARGETS; TARGETING INNATE IMMUNITY PROTEIN KINASE SIGNALLING; SELECTIVELY NONSELECTIVE KINASE INHIBITION | 44 | Ambit Biosciences Corp |
| METABOLITE IDENTIFICATION ALL-IN-ONE ANALYSIS LIQUID CHROMATOGRAPHY/HYBRID QUADRUPOLE TIME-OF-FLIGHT MASS SPECTROMETRY-COLLISION ENERGY SWITCHING METHOD | 28 | Waters Corp |
| IN-VITRO CYTOCHROME P450 INHIBITION DATA; IN-VITRO DRUG DISCOVERY DATA; PREDICTING IN-VIVO DRUG INTERACTIONS; CLINICAL DRUG-DRUG INTERACTIONS | 26 | Pfizer Inc |
| VIRTUAL SCREENING PROTEIN-LIGAND DOCKING METHOD ARTIFICIAL ENRICHMENT AVOIDANCE; VIRTUAL SCREENING USING MULTIPLE BIOACTIVE REFERENCE STRUCTURES | 26 | GlaxoSmithKline |
| TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED; VILDAGLIPTIN-GLIMEPERIDE TREATMENT EFFICACY-SAFETY; TYPE 2 DIABETES FAILING THIAZOLIDINEDIONE MONOTHERAPY | 25 | Merck & Co, Inc |
| POLYETHYLENIMINE (PEI)-COMPLEXED SIRNA IN-VIVO; NONINFLAMMATORY SYNTHETIC SIRNA MEDIATING POTENT GENE SILENCING IN-VIVO | 22 | Alnylam Pharmaceuticals, Inc |
| G-CSF-INITIATED MYELOID CELL MOBILIZATION-ANGIOGENESIS ANTI-VEGF THERAPY TUMOR REFRACTORINESS MEDIATION; TUMOR-BEARING HOST DIRECTLY PROMOTES TUMOR ANGIOGENESIS | 21 | Genentech inc |
| 2004-2010_3 | ||
Corporate Research Fronts
Research Fronts
About
Featured Image:
Singapore's central business district is pictured at dusk, December 30, 2009.
REUTERS/Tim Chong.